News and Announcements
Martin Aircraft Limited announces supply of Series 1 Jetpacks
- Published February 28, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Martin Aircraft Limited (ASX:MJP) is pleased to announce that it has entered into an agreement today with Shenzhen KuangChi Dream Technology Company Limited for the supply of four Series 1 Jetpacks and one pilot training simulator.
KEY TAKEAWAYS:
- Shenzhen KuangChi Dream Technology Limited is a subsidiary of Martin Aircraft’s majority shareholder.
- The sale follows the successful Martin Jetpack Shenzhen flight demonstration in December 2015 demonstrating the strong desire to see the commercialization of the jetpack product in China.
- Payment terms are 80% payment on delivery and obtaining NZ Certificate of Registration and 20% payment on final customer receipt and confirmation of acceptance tests.
- Martin Aircraft anticipates completion of all payment milestones in mid-2017 for three Series 1 Jetpacks and delivery of the final and fourth Series 1 Jetpack in later 2017.
“It is anticipated that subject to obtaining necessary regulatory approval as an experimental aircraft, Martin Aircraft will initially operate and support the aircraft in China under a Service and Support Agreement still to be negotiated.”
Martin Aircraft Company Limited is the maker of the innovative Martin Jetpack, the world’s first practical Jetpack, which is poised to alter the dynamics of aviation.
Initially designed as a personal Jetpack for individuals in the leisure market, the company soon realised the ground-breaking role the Jetpack could play in saving and improving human lives. As well as recreational usage, its potential applications span first response, search and rescue, military, and commercial, both in a manned and unmanned capacity.
Company Updates
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
Backed By Leading Investment Groups and Family Offices
